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Abstract 
Effective symptom management for a patient with a palliative 
diagnosis can be challenging. There are some symptoms that may be more difficult to control and 
understand than others. Delirium, as a symptom, may well prove to be a significant challenge for all 
involved, leaving family and professionals perplexed and exhausted. 
Understanding the predisposing factors and the manifestations may aid the health professional in 
the assessment and identification of this distressing symptom facilitating more effective 
management and care of those who are approaching the end of life. This article attempta to address 
some of the challenges and offer a number of suggestions that may aid in identifying delirium in 
patients at the end of life but also examines some of the dilemmas when attempting to treat 
delirium. 
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Ensuring those reaching the end of life receive proactive, evidence-based care is paramount and 
symptom management is crucial in facilitating a dignified, peaceful  death. Providing  effective  relief 
from symptoms that are perceived as distressing should be a key priority for health professionals 
(Brown, 2012). The health professional needs to ensure that a patient-centred approach is adopted 
with an attempt to maintain patient autonomy, The patient should be encouraged to prioritise 
problems and symptoms that are distressing or important to him or her during the assessment and 
care planning process. Unfortunately, patients may have complex needs or symptoms that are 
difficult to manage e.g. intractable vomiting, neuropathic or bone pain. Delirium is one symptom at 
the end of life that may also pose a management dilemma. 
This article aims to clarify and substantiate existing knowledge surrounding delirium, to help in the 
management of delirium for a patient with cancer who is reaching the end of life.A clear 
understanding of delirium, its presentation and the many pre-disposing factors can help health 
professionals identify the condition and address the impact it has on the patient and his or her loved 
ones. 
Within palliative care, more recently referred to as supportive and palliative  care, knowledge  and  
expertise in symptom management for those with life limiting illness, such as cancer or heart failure 
is an intrinsic aspect of the service provided (Twycross, 1997; World Health Organization, 2007, 
National Cancer Action Team, 2007 [AQ1: See ref list]; National Council for Palliative Care, 2012). The 
pressure of expectation from patients, lay carers and loved ones of ensuring that this is in place can 
leave supportive care teams feeling exhausted (Spiller and Keen 2006). As a consequence, it is 
important for any member of a supportive care team to study any element of care delivery or 
symptom management that is not understood, but also to maintain their knowledge and 
understanding as encompassed by the health professional’s duty of care (Nursing and Midwifery 
Council, 2015 and Care Quality Commission (CQC) 2013. 
 
Background 
Delirium or acute confusional state,is a generalised disturbance of cognitive function, perception 
and/or consciousness, and may be as a consequence of a number of predisposing factors e.g. post-
operative confusion, intensive care (ICU) delirium (formally referred to as ICU psychosis) or infection 
(Meagher and Leonard, 2008, National Institute for Health and Care Excellence (NICE) 2010). NICE 
has produced guidelines surrounding the assessment and treatment of delirium but makes it clear 
that the guidance does not look at those receiving end of life care (NICE 2010). 
Delirium has been under-reported in all healthcare settings, which has been attributed to a poor 
knowledge base and difficulties in identifying delirium (NICE, 2010). Dementia and delirium are often 
confused as they may present with similar features e.g. dementia may be associated with a 
confusional state and poor perception, which is generally of a progressive nature, while delirium is 
an acute and rapidly progressing condition with sudden changes to the patient’s presentation. The 
key difference between the two, in addition to the rate of progression, is the reversibility, delirium 
may have some potential for reversibility but dementia, in its progressive state, has no reversibility 
(NICE 2010). One must be cautious, however, as a patient who has a dementia diagnosis could also 
have reversible delirium due to another underlying condition e.g. infection. 
It has been suggested that 70% of patients presenting with delirium  fail  to  be  diagnosed  and  
some  of  these  may  be patients approaching the end of life (Waszinski, 2004). In the UK, the initial 
release of recognised guidelines developed by NICE in 2010  initiated  and renewed a degree of 
interest in the management of delirium. These guidelines followed five reviews from the Cochrane 
Collaboration based on the problems surrounding delirium [Note: on checking the citations  of  the  
reviews  they  were not all first published in 2009, have reworded] but these do not address end of 
life for patients with cancer. Four of the reviews cover prevention of delirium in hospitalised patients 
(Siddiqi et al, 2007), the use of antipsychotics (Lonergan et al, 2007), the use of benzodiazepines 
(Lonergan et al, 2009) and the effectiveness of cholinesterase inhibitors for delirium (Overshott et al, 
2008). The fifth was not applicable to this discussion as it related solely to dementia. The four 
Cochrane reviews do contain some valuable information and practicalities for trying to establish best 
practice in the management of delirium. 
A more recent review by the Cochrane Collaboration (2014) examines the prevention of delirium, 
which is extremely important as it may increase the risk of premature mortality and the length of 
stay but also for patients with a dementia diagnosis, it can exacerbate the condition (CC 2014). It 
also reports that the prevention is of the upmost importance, as delirium itself carries a substantial 
financial cost but also has a significant effect on quality of life for those with a terminal diagnosis 
Additionally it also continues to be underdiagnosed in this patient group (CC 2012)  
NICE (2010) and NHS Scotland (2011have identified that haloperidol should be the drug of choice for 
patients presenting with irreversible delirium. Despite the fact that both NICE (2010) and NHS 
Scotland (2011) advocate that haloperidol is useful in the treatment of delirium the Cochrane 
researchers acknowledged (2012) that it was useful in the short term but one needs to consider that 
it may cause adverse extra pyramidal symptoms among some patients (Lonergan et al, 2007). When 
they compared haloperidol with chlorpromazine both groups initially experienced cognitive 
improvement, however, those treated  with  chlorpromazine  experienced a deterioration in their 
cognitive function 48 hours after initiating treatment. Within this review, the only study they could 
identify was one by Breitbart (1996) despite this review taking place in 2012, which demonstrates 
the lack of current available evidence upon which to base out clinical practice. Limitations identified 
are that it was a small study  and its focus was on patients with Auto Immune Deficiency Syndrome 
but they  were at the  advanced stage  of their disease so there may be transferable and 
generalizable aspects despite this review specifically focusing on cancer patients.  
The Cochrane reviews reported it was evident  that although there had been some studies and 
several randomised controlled trials undertaken, more should be done to ensure the prevention  of  
delirium  (Lonergan  et  al, 2007; Siddiqi et al, 2007; Overshott et al,2008; Lonergan et al, 2009; ). The 
subsequent Cochrane review (2014) did not examine terminal care but care of those in long-term 
care so again limited application to the focus of this paper. Again, the researchers could only identify 
two papers for their review as they either failed to focus on delirium or its treatment, some 
examined other health conditions rather than delirium and two were not in the long-term setting  
therefore  excluded (one was based at home and the other was acute care. Neither were treated for 
delirium at the end of life. 
NICE released the guidelines Delirium: diagnosis, prevention and management in 2010, which 
discuss the importance of preventing delirium. The guidance is primarily focused on preventing 
delirium in adults in hospital and long-term care establishments, aiming to reduce the length of 
hospital stays. Although this guidance does provide positive information to ensure best practice is 
upheld, it provides a disclaimer that the guidelines do not cover, children, people withdrawing from 
alcohol and people receiving end of life care. 
With the Cochrane reviews and the guidance from NICE surrounding delirium it was hoped that 
some direction would be located in relation to patients at the end of life with cancer, but as NICE did 
not include patients at the end of life it is evident that this has yet to be addressed (Siddiqi et al, 
2007; Agar et al, 2008). 
Although identifying positive interventions for those suffering with delirium at the end of life with 
cancer would be a great benefit, this requires valid research studies in order to provide robust 
evidence on which to underpin practice. The difficulty in completing research in palliative care with 
the use of reliable and validated randomised controlled trials is an ethical one, when dealing with 
those who are dying, an instinct for most is to protect the terminally ill rather than burden them 
with questions or cause distress (Ross and Cornbleet, 2003). 
 
Literature review 
Reliable evidence on which to underpin care surrounding delirium at the end of life for a cancer 
patient, one may argue, is not widely available, or suitably explored. During the author’s search for 
evidence, which incorporated a Medline, CINAHL and PsychInfo database search, there appeared to 
be a limited number of comparable studies, other than by the same author (Meager et al 2007, 
2008), which affects the reliability as partiality is likely to be evident, making it difficult to effectively 
compare and contrast. Despite the  paucity  of  national  guidance  on  delirium at the end of life for 
a cancer patient, delirium was being discussed in the 1980s-90s by reputable authors in palliative 
care, such as Robert Twycross (1997). Various researchers internationally have also taken an interest 
in the complexities of delirium, such as Morita et al (2007),Trzepacz et al (1999), Meagher and 
Leonard (2008) and more recently Boettger et al (2012). The effort made by such researchers has 
enabled a greater understanding of delirium, for example, the causes and reversibility potential but 
also its sub-categories e.g. the hypoactive and hyperactive associations, which in turn have 
facilitated progression in the management and  treatment. One may argue that there is still limited 
data to suggest clearly, how to apply assessments and best practice to patients at the end of life with 
cancer (Agar et al, 2008). 
 Definition of delirium at the end of life for a cancer patient 
Although this discussion will focus on patients with cancer at the end of life it is important to be 
cognisant that delirium can affect anyone at  any  time  of  life. What  one can acknowledge are 
some of the predisposing factors in non-end-of-life care as some of these may be predisposing 
factors in those  reaching  the  end  of  life  e.g. a  period  of ill health, or increasing age (Meagher 
and Leonard, 2008; NICE, 2010). Delirium is thought by many to be reversible if the episode is 
identified early enough, through improved assessment and identification but as already established 
earlier, this tends to not be the case for those approaching the end of life (CC 2012). They estimate 
that it is reversible in a maximum of 50% of cases for those with a terminal diagnosis (Gagnon, 2012) 
[AQ14: missing from list] but with the risk that the longer it is left untreated, the more difficult and 
improbable the reversibility becomes (George and Lee 2005). Delirium at the end of life may present 
a diagnostic challenge, as its presentation may be similar or the same as reversible delirium, with no 
clear indication to suggest which the patient is suffering from (Spiller and Keen, 2006).The difficulty 
then arises when attempts are being made to define what delirium is at the end of life. Boettger et al 
(2012) attempted to define delirium as a neuropsychiatric disorder, suggesting it is characterised by 
an array of attributes, varying from cognitive disturbances and underlying causes e.g. infection, 
hypercalcaemia, opioid toxicity. In addition it may incorporate not simply physical symptoms but 
also spiritual or emotional distress.This delirium may be termed, ‘agitated delirium, terminal 
delirium, terminal restlessness, terminal agitation, existential distress or terminal distress’ (CC 2012 
pg 3) 
In concurrence to some degree, but equally in comparison to this, it has been concluded by Brooker 
and Nicol (2007 [AQ15: see ref list]) that delirium, is neurological but presents in two variances; 
cerebral and extracerebral. 
The suggestion that the cerebral characteristic is inclusive of all conditions that are primarily ‘post 
event’ such as encephalitis, transient ischaemic attacks, raised intracranial pressure or post seizure 
would certainly attribute to an onset of delirium (Twycross, 1997) [AQ16: I don’t  understand what 
you mean here, needs rewording]. But this theory would not always apply to a patient who is in the 
end stages of life as a result of cancer as there may be a number of contributing factors (highlighted 
earlier) which could be difficult to determine when considering a patients with a limited life 
expectancy. Extracerebral incidences, however, such as drug/alcohol withdrawal, constipation and 
infection are increasingly identified as  a  major  cause  of  delirium for the patient with cancer; 
infection risks increase  as  the body  is  deteriorating  and  constipation  becomes  prevalent as the 
patient becomes less mobile and takes a significantly reduced diet (Spiller and Keen, 2006). Both of 
these features present with similar traits; poor attention to external stimuli, hallucinations, mood 
changes and paranoia (Brooker and Nicol, 2007), notably these may be indicative of many conditions 
affecting the wellbeing of one’s mind but as suggested these may be numerous in a patient suffering 
with cancer at the end of life (Pessin et al, 2002). It is fair to say a cancer patient at the end of life 
may well be experiencing these symptoms but not as a result of delirium, it may also be due to a loss 
of hope and control (Pessin et al, 2002, Holloway et al, 2010). 
Another conjecture that may aid with the definition of delirium is based on the work of Spiller and 
Keen (2006). They have clearly reinforced the idea that there are two types of delirium; their focus is 
predominantly hypoactive delirium, which leaves the patient feeling  lethargic  and  withdrawn, but 
does also refer to the better understood hyperactive delirium (presence of hallucinations and 
agitation). Although the authors report significant correlation within the results, empowering the 
use of assessment tools, it is clear that the data from this study does not clearly coalesce; also it 
does not consider which of the patients with delirium came from home or hospital, as it would be 
expected, when considering evidence brought up by Siddiqi et al (2007) and NICE (2010), that those 
from hospital should be at a higher risk of developing  delirium. In relation to the areas explored, it 
may be fair to suggest that delirium can be defined as an acute confusional state or altered 
consciousness that can be triggered by either intrinsic or extrinsic elements (Spiller and Keen, 2006). 
 
The dissimilarity of reversible and irreversible delirium 
As already identified, delirium can be reversible or irreversible (Leonard et al, 2008), hypoactive or 
hyperactive (Spiller and Keen, 2006) and caused by intrinsic or extrinsic factors (Spiller and Keen, 
2006; Brooker and Nicol, 2007). Although acclaimed already as a challenge, being able to recognise 
and diagnose which variant the patient is suffering from should facilitate appropriate treatment but 
a patient presenting with [AQ17: both?] hypo and hyperactive delirium may be an additional 
challenge (NICE, 2010). 
A study carried out by Leonard et al (2008) suggests that reversible delirium  presents  with  either  
one  or  sometimes, a number of intrinsic and extrinsic factors (however, the study examines 
patients with a number of diseases and illnesses therefore its transferability to end of life care may 
be questioned and may indeed be limited). Intrinsic elements include metabolic problems, central 
nervous systems (CNS) infections, systemic neoplasm, CNS neoplasm, organ failure, cerebrovascular 
and systemic infections (Leonard et al, 2008). Despite the  fact that  this  paper does  not  focus on  
end  of life care specifically, the  intrinsic  elements  described  can be associated with some of the 
presentations seen. Drug intoxication, drug/alcohol withdrawal and traumatic brain injury were 
listed as the extrinsic elements, and these have little resemblance to  end  of  life  care  issues  
(Leonard  et al, 2008). Although  this  study  investigated  the  differences between the two types of 
delirium, it is appears  that  both types of delirium may share similar symptoms and as a result there 
may be similar causes. If a patient is approaching the end of life, one has to consider the  dilemmas  
associated with spending time trying to assess for  reversibility  rather than simply treating the 
delirium. Delays in treatment while assessing the patient may result in distress for both the the 
person and their family. Assessing the patient  individually and recognising when the  end  of  life  is  
approaching  may be factors to consider when presented with a patient who appears to be suffering 
from delirium. One  could  suggest that focusing on providing an effective nursing environment i.e. 
quiet and calm, may be more beneficial than managing and diagnosing the cause at this stage in the 
patients journey. What is evident in Leonard et al’s (2008) study is that the intrinsic and extrinsic 
factors are evident at some point in all cases and types of delirium, but the question surrounding the 
reversibility  is  unclear  with  the  exception  of  organ  failure, this  is  predominantly  irreversible. 
However, it  is  clear  that there are significant predisposing factors to delirium (Siddiqi et al, 2007) 
which include; bone metastases, haematological malignancy,  advanced  age,  cognitive  impairment,  
and  low albumin  level  (Ljubisavljevic  and  Kelly,  2003),  therefore taking a more proactive 
approach and recognising these risk factors may result in more prompt treatment. 
Delirium may be a manifestation from an underlying cause such as cancer and exacerbated by 
another intrinsic element for example, an infection. But it is still not clear if delirium at the end of life 
is reversible or an innate part of the dying process. 
 
Conclusion 
What is apparent within the evidence examined is that delirium manifests in a number of ways and 
consequently, may leave health professionals confused in relation to its diagnosis and management. 
Hypoactive delirium can usually present with traits similar to depression, for example, withdrawal 
from day to day activities, family and eating and drinking (Spiller and Keen, 2006). It is also thought 
that health professionals with specific expertise in the field of palliative care may also miss the 
symptoms of hypoactive delirium, believing that the patient is either depressed or just generally 
deteriorating in condition (Spiller and Keen, 2006). 
Future work should be undertaken to examine and identify best practice in managing delirium. 
Developing tools to aid assessment and treatment of delirium would benefit practice but currently 
we should endeavor to raise awareness and assessment skills in order to recognise and treat it as a 
serious symptom promoting dignity in patients approaching the end of life.                                                                                
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